Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13996668 | 0.88 | NPC1 (0.50) | NPC1RAB9AALDH1A1POLBAKR1C3 | |
| SCHEMBL23343714 | 0.85 | NPC1 (0.46) | NPC1RAB9AALDH1A1POLBAKR1C3 | |
| SCHEMBL2724979 | 0.84 | NPC1 (0.55) | NPC1RAB9AALDH1A1POLBAKR1C3 | |
| SCHEMBL14269924 | 0.77 | RAB9A (0.49) | NPC1RAB9AALDH1A1POLBAKR1C3 | |
| SCHEMBL1453847 | 0.76 | GAA (0.43) | ALDH1A1KMT2A | |
| SCHEMBL23084782 | 0.76 | MAPT (0.48) | ALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL21790803 | 0.74 | EPHX1 (0.42) | ALDH1A1POLBSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL21799923 | 0.74 | MAPT (0.43) | ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL22600368 | 0.74 | GAA (0.46) | RAB9AALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL873032 | 0.74 | AKR1C3 (0.61) | NPC1RAB9AALDH1A1AKR1C3NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071308-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071308-A1 | Benzene, Pyridine, and Pyridazine Derivatives | CDK4, P2RX4, MKI67 | NPC1 4242/4885RAB9A 3778/4885ALDH1A1 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.